Sort by

Send to

Choose Destination

Search results

Items: 4


Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR, et al.

J Infect Dis. 1998 Jun;177(6):1664-73.


NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, De Taisne C, Hui GS, Chang SP, Church P, Hollingdale MR, Kaslow DC, Hoffman S, Guito KP, Ballou WR, Sadoff JC, Paoletti E.

Infect Immun. 1996 Sep;64(9):3833-44.


Decreased counts of blood neutrophils, monocytes, and platelets in human immunodeficiency virus-infected children and young adults treated with diethyldithiocarbamate.

Shenep JL, Hughes WT, Flynn PM, Roberson PK, Behm FG, Fullen GH, Kovnar SG, Guito KP, Brodkey TO.

Antimicrob Agents Chemother. 1994 Jul;38(7):1644-6.


Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants.

Holmes SJ, Fritzell B, Guito KP, Esbenshade JF, Blatter MM, Reisinger KS, Keyserling HL, Rothstein EP, Bernstein HH, Feldman S, et al.

Am J Dis Child. 1993 Aug;147(8):832-6.


Supplemental Content

Loading ...
Support Center